Pleuropulmonary Pathology in Patients With Rheumatic Disease

2012 ◽  
Vol 136 (10) ◽  
pp. 1242-1252 ◽  
Author(s):  
Frank Schneider ◽  
James Gruden ◽  
Henry D. Tazelaar ◽  
Kevin O. Leslie

Thoracic manifestations of rheumatic disease (RD) are increasingly recognized as a significant cause of morbidity and mortality worldwide. Rheumatologic underpinnings have been identified in a significant proportion of patients with interstitial lung disease. The 5 RDs most frequently associated with pleuropulmonary disease are (1) rheumatoid arthritis, (2) systemic lupus erythematosus, (3) progressive systemic sclerosis, (4) polymyositis/dermatomyositis, and (5) Sjögren syndrome. The onset of thoracic involvement in these diseases is variable. In some patients, it precedes the systemic disease or is its only manifestation. Moreover, there is a wide spectrum of clinical presentation ranging from subclinical abnormalities to acute respiratory failure. Histopathologically, the hallmark features of thoracic involvement by RD are inflammatory, targeting one or more lung compartments. The reactions range from acute to chronic, with remodeling by fibrosis being a common result. Although the inflammatory findings are often nonspecific, certain reactions or anatomic distributions may favor one RD over another, and occasionally, a distinctive histopathology may be present (eg, rheumatoid nodules). Three diagnostic dilemmas are encountered in patients with RD who develop diffuse lung disease: 1) opportunistic infection in the immunocompromised host, 2) drug toxicity related to the medications used to treat the systemic disease, and 3) manifestations of the patient's known systemic disease in lung and pleura. To confidently address the latter, the 5 major RDs are presented here, with their most common pleuropulmonary pathologic manifestations, accompanied by brief clinical and radiologic correlations.

Medicina ◽  
2021 ◽  
Vol 57 (10) ◽  
pp. 1094
Author(s):  
Motoi Ugajin ◽  
Hisanori Kani ◽  
Hideo Hattori

Background and objectives: Bronchoalveolar lavage (BAL) is commonly performed to evaluate diffuse lung disease and occasionally to identify alveolar hemorrhage. However, the clinical impact of alveolar hemorrhage and its risk factors in patients with diffuse lung disease have not been clarified. Materials and Methods: We retrospectively analyzed the medical records of all patients who underwent BAL to evaluate diffuse lung disease from January 2017 to December 2020. Alveolar hemorrhage was defined as progressive hemorrhagic BAL fluid or the presence of ≥20% hemosiderin-laden macrophages in the BAL fluid. Logistic regression analysis was performed to assess the association between alveolar hemorrhage and other factors. Results: Sixty subjects were enrolled in this study. Alveolar hemorrhage was observed in 19 subjects (31.7%) with idiopathic interstitial pneumonia, acute respiratory distress syndrome, interstitial pneumonia with autoimmune features, drug-induced lung injury, eosinophilic pneumonia, adenocarcinoma, and systemic lupus erythematosus. The use of anticoagulants was a significant risk factor for alveolar hemorrhage (odds ratio 7.57, p = 0.049). Patients with alveolar hemorrhage required intubated mechanical ventilation more frequently (63.2% vs. 24.4%, p = 0.005) and had higher in-hospital mortality rates (26.3% vs. 4.9%, p = 0.028) than those without alveolar hemorrhage. Conclusions: Alveolar hemorrhage was observed in various etiologies. The use of anticoagulants was a significant risk factor for alveolar hemorrhage. Patients with alveolar hemorrhage showed more severe respiratory failure and had higher in-hospital mortality than those without alveolar hemorrhage.


Pulmonology ◽  
2018 ◽  
Vol 24 (1) ◽  
pp. 23-31 ◽  
Author(s):  
L.M. Almeida ◽  
B. Lima ◽  
P.C. Mota ◽  
N. Melo ◽  
A. Magalhães ◽  
...  

2021 ◽  
Vol 80 ◽  
pp. 23-29
Author(s):  
Diane Abdel-Latif Thomasson ◽  
Rola Abou Taam ◽  
Laureline Berteloot ◽  
Sonia Khirani ◽  
Lucie Griffon ◽  
...  

2009 ◽  
Vol 15 (4) ◽  
pp. 597-611
Author(s):  
Natália Melo ◽  
Sandra Figueiredo ◽  
António Morais ◽  
Conceição Souto Moura ◽  
Paulo Pinho ◽  
...  

Author(s):  
Alba Torrent-Vernetta ◽  
Mirella Gaboli ◽  
Silvia Castillo-Corullón ◽  
Pedro Mondéjar-López ◽  
Verónica Sanz Santiago ◽  
...  

2018 ◽  
Author(s):  
Gerald W. Staton Jr ◽  
Eugene A Berkowitz ◽  
Adam Bernheim

Parenchymal lung disease often presents on imaging with particular patterns that allow for recognition of certain clinical entities that may form the basis for an imaging differential diagnosis. Focal pulmonary opacities and multi-focal pulmonary opacities may be due to an infectious or neoplastic etiology, amongst other possibilities. Segmental/lobar opacities are also associated with a set of differential diagnoses. Diffuse parenchymal disease, while also associated with some infections and neoplasms, can additionally be seen in the setting of pneumoconioses and several idiopathic interstitial pneumonias. Combining clinical information including laboratory results with the imaging findings on chest radiography and computed tomography (CT) allows the physician to formulate an appropriate differential diagnosis or reach one specific diagnosis. This review contains 16 figures, 4 tables and 32 references Keywords: Pulmonary Opacity, Pulmonary Infection, Eosinophilic Pneumonia, Lipoid Pneumonia, Pulmonary Tuberculosis, Organizing Pneumonia, Lung Cancer, Diffuse Lung Disease, Pneumoconiosis, Idiopathic Interstitial Pneumonia


2019 ◽  
Vol 54 (1) ◽  
pp. 21-29
Author(s):  
Kimberly G. Kallianos ◽  
Brett M. Elicker ◽  
Travis S. Henry

Sign in / Sign up

Export Citation Format

Share Document